Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984508 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL5171370 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL495756 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL1481008 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL638912 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL640670 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL13537629 | 0.90 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6158017 | 0.90 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6158094 | 0.90 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6158009 | 0.90 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220417-A1 | Processes for preparation of n-protected-beta-amino alcohols and n-protected-beta-amino epoxides | AJINOMOTO CO., INC. (JP) | 2004-11-04 | — | — | US | claimed |
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080070910-A1 | Therapeutic compounds and methods | GILEAD SCIENCES, INC. | 2008-03-20 | — | — | US | disclosed |
| EP-1346979-A1 | PROCESSES FOR PREPARATION OF N-PROTECTED- -AMINO ALCOHOLS AND N-PROTECTED- -AMINO EPOXIDES | Ajinomoto Co., Inc. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207735-A1 | 1-Amino Linked Compounds | DPP4, DPP3, DPP9 | KLK5 3927/4885ATM 4603/4885PSEN1 3565/4885 |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | KLK5 438/4885ATM 3215/4885PSEN1 609/4885 |
| US-20040220417-A1 | Processes for preparation of n-protected-beta-amino alcohols and n-protected-beta-amino epoxides | NPEPPS, DNPEP, ANPEP | KLK5 3494/4885ATM 3659/4885PSEN1 425/4885 |
| US-20080070910-A1 | Therapeutic compounds and methods | SERPINB1, ABCC1, SERPINB6 | KLK5 438/4885ATM 3215/4885PSEN1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.